Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Pandemrix in Elderly
NCT00971425Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Primary completion
- Nov 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Q-Pan H1N1 in influenza (2 arms), sponsored by GSK. Primary endpoints: Geometric Mean Titers of Antibodies Against Pandemrix Vaccine Strain at Day 42, Number of Seroconverted Subjects for Antibodies Against Pandemrix Vaccine Strain at Day 42 and 1 more. Started Sep 2009; status: completed.
02
Drugs
Q-Pan H1N1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00971425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00971425.